Alzheimers Research Paper

Non-pharmacological interventions, such as validation therapy, are the first line approach to manage BPSD. However, in emergency cases where there is safety risk for the person with dementia and others, the pharmacological intervention or psychotropic drug are used. Psychotropic drug includes neuroleptics, anxiolytics and antidepressants. Additionally, to improve cognitive function, memory enhancement drugs such as cholinesterase inhibitors are

We carried out an extensive review of the literature on non-pharmacological treatments for dementia using Medline and other related searches, but this is not intended to be a formal systematic review.

The FDA recently has allowed two treatments to be used for Alzheimer patients. One of the treatments is a Partial Glutamate Antagonist, which is an important transmitter to the brain. It is said that Glutamate helps patients more than sugar pills do, however; it is said that too much

Among these are increasing physical activity, having a diet rich in fruits and vegetables, maintaining social engagement, and participating in intellectually stimulating activities. I informed her that the approved treatments for Alzheimer’s disease are designed to enhance the communication between nerve cells. In some individuals, this will lessen the symptoms. However, these treatments will not prevent the progression of the disease.

With the growing number of people becoming diagnosed, and experiencing symptoms of Alzheimer’s disease, we must begin to take precautions and somehow attempt to gain knowledge of how the disease can be better treated, and ultimately prevented.

As Alzheimer’s disease progresses into the mild stage, memory loss becomes worse and changes in other cognitive abilities are evident. These problems include: getting lost, trouble handling money and

medications do not cure the disease. It is documented that once the memory is lost, it cannot be

There is no cure for Alzheimer’s. But drug and non-drug treatments may help with both cognitive and behavioral symptoms

In drug therapy, studies show that cholinesterase blocker can reduce psychiatric symptoms in patients with Alzheimer 's disease. Moreover, Alzheimer 's disease could cause insomnia, irritability, visual illusion, delusions and other symptoms. The drug such as hypnotics, antipsychotic drugs, antiepileptic drugs, anti-depression drugs will have good effects to those symptoms. Furthermore, study shows that neuro protective agent Namenda can block glutamate for the destruction of brain cells. Therefore, drugs that slowing down the continuing loss of life skills are currently the main treatments of moderate and severe dementia.

There are several different types of schedules that can be as simple as a “To do List” or as complex as a plan for a construction project.

Burcham and Rosentheal (2016) talk about a medication called Aricept. Aricept is a cholinesterase inhibitor that was approved by the FDA to treat early stages of Alzheimer's disease. Cholinesterase inhibitors prevent the breakdown of acetylcholine, a chemical in the brain and the body that helps to communicate with other cells in the body. For AD patients, Aricept would increase the amount of acetylcholine and improve the function of neuron that have not been destroyed. Furthermore, Aricept does not cure the disease, it helps delaying the disease and preventing symptoms form becoming worse.

Alzheimer's Disease is a condition that affects 50% of the population over the age of eighty five, which equals four million Americans each year. It is becoming an important and high-profile issue in today's society for everyone. There are rapid advancements being made in the fight against this disease now more than ever, and the purpose of this essay is to educate the public on the background as well as the new discoveries. There are many new drugs that are being tested and studied every day which slow down, and may even halt the progress of the disease.

Scientists may have discovered a drug that can help patients with Alzheimer's disease. The drug named solanezumab can slow down the rate of memory loss in patients suffering from mild Alzheimer's.

Pharmacological interventions of treating AD are by using anti-dementia drugs. Anti-dementia drugs are acetylcholinesterase inhibitors (AChEIs) and memantine. AChEIs which are donepezil, galantamine and rivastigmine have marketing authorisation in UK for treatment of mild to moderate AD. AChEIs work by preventing acetylcholinesterase enzyme from breaking down acetylcholine so that the concentration and duration of acetylcholine at neurotransmission sites increase [1]. Donepazil is a reversible, specific AChEI. Galantamine is a reversible inhibitor of acetylcholinesterase and it can modulate activity at nicotinic receptor. Rivastigmine is a reversible non-competitive inhibitor of acetylcholinesterase and butyrylcholinesterase. AChEI can cause unwanted side effects such as nausea, vomiting, diarrhoea and dizziness. Treatment should be started at low dose and the dose can be titrate up gradually depend on response and tolerability

Cholinesterase inhibitors have been used to treat memory impairment although most commonly prescribed in Alzheimer’s disease. Greene et al (2000) carried out an open trial study to study the role of donepezil in 17 MS cases, patients.There was improvement in attention, memory, executive functioning, as well as different aspects of behavior. In a double-blind placebo controlled trial of 69 patients, Krupp and colleagues (2004) found improvements with donepezil on performance of the Selective Reminding Test (SRT), a measure of verbal memory, as well as self-reported memory.